Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04452214 · ClinicalTrials.gov registry record · Phase 1

A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors

A Phase 1 study of Carcinoma, Non-Small Cell Lung and Head and Neck Squamous Cell Carcinoma, sponsored by Cantargia AB.

Completed
Registry status
Phase 1
Development phase
19
Enrollment target
3
Study locations

NCT04452214 is a Phase 1 study of Carcinoma, Non-Small Cell Lung and Head and Neck Squamous Cell Carcinoma that has completed, run by Cantargia AB. The registered enrollment target is 19 participants, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (94% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04452214, a Phase 1 study of Carcinoma, Non-Small Cell Lung and Head and Neck Squamous Cell Carcinoma, has completed, sponsored by Cantargia AB.

COMPLETED
Registry status
Phase 1
Development phase
19 participants
Enrollment target
3
Study locations

Study Summary

This study will consider the safety and effectiveness of a study drug, CAN04, in combination with pembrolizumab, in the treatment of incurable or metastatic non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma, urothelial cancer, or malignant melanoma. The study aims to establish a recommended dose of CAN04 in combination with the standard dose of pembrolizumab (Part 1), and in combination with pembrolizumab standard dose, and Standard of Care carboplatin and pemetrexed (Part 2 - subjects with stage IV, non-squamous metastatic NSCLC). CAN04, pembrolizumab. carboplatin and pemetrexed will be administered intravenously.

Conditions Studied

Carcinoma, Non-Small Cell Lung Head and Neck Squamous Cell Carcinoma Urothelial Carcinoma Malignant Melanoma

Interventions

  • DRUG Pembrolizumab
  • DRUG Carboplatin
  • DRUG Pemetrexed
  • DRUG CAN04

Study Locations (3)

Colorado

  • University of Colorado Cancer Center - Aurora

Florida

  • Florida Cancer Specialists & Research Institute - Lake Mary

Pennsylvania

  • Hospital of The University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2020-09-24
Est. Completion 2023-06-28
Phase Phase 1

Sponsor

Cantargia AB

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04452214

The ClinicalTrials.gov registry entry for NCT04452214 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (94% lower). The listed sponsor is Cantargia AB, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.

NCT04452214 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Colorado, Florida, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT04452214 about?

NCT04452214 is a clinical study titled "A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors". This study will consider the safety and effectiveness of a study drug, CAN04, in combination with pembrolizumab, in the treatment of incurable or metastatic non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma, urothelial cancer, or malignant melanoma. The study aims to establis...

What is the current status of trial NCT04452214?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2020-09-24. Estimated completion is 2023-06-28.

What conditions does trial NCT04452214 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma, Malignant Melanoma.

What interventions are being tested in trial NCT04452214?

The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Pemetrexed (DRUG), CAN04 (DRUG).

Who is sponsoring clinical trial NCT04452214?

This trial is sponsored by Cantargia AB, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04452214 being conducted?

This trial has 3 study locations across Colorado, Florida, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Non-Small Cell Lung

All registered trials for this condition

Head and Neck Squamous Cell Carcinoma

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.